

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee Jul 2018 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved	N/A
2	Azelastine, fluticasone	Dymista	Ear, nose, and oropharynx	Approved	N/A
3	Carboxymethylcellulose sodium/Glycerin/Polysorbate 80	Optive Advanced	Eye	Approved	N/A
4	Carfilzomib	Kyprolis	Malignant disease and immunosuppression	Approved in principle	N/A
5	Cerebrolysin	Cerebrolysin	Cardiovascular system	Rejected	Lack of high quality level of evidence to demonstrate its efficacy
6	Cetuximab	Erbitux	Malignant disease and immunosuppression	Approved	N/A
7	Crizotinib	Xalkori	Malignant disease and immunosuppression	Pending	Pending further information
8	Dutasteride/Tamsulosin	Duodart	Obstetrics, gynaecology, and urinary-tract disorders	Rejected	Alternative(s) available in HADF with comparable benefits
9	Elbasvir/Grazoprevir	Zepatier	Infections	Approved	N/A
10	Eribulin	Halaven	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
11	Glecaprevir/Pibrentasvir	Maviret	Infections	Approved	N/A
12	Ixazomib	Ninlaro	Malignant disease and immunosuppression	Approved in principle	N/A
13	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Pending	Pending further information
14	Milrinone	Primacor	Cardiovascular system	Approved	N/A
15	Nivolumab	Opdivo	Malignant disease and immunosuppression	Approved	N/A
16	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
17	Pregabalin	Lyrica	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits

18	Ranolazine	Ranexa	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
19	Ribociclib	Kisqali	Malignant disease and immunosuppression	Approved	N/A
20	Selexipag	Uptravi	Cardiovascular system	Rejected	Insufficient evidence of long-term clinical outcome benefits
21	Sofosbuvir, ledipasvir	Harvoni	Infections	Approved	N/A
22	Tafamidis meglumine	Vyndaqel	Central nervous system	Pending	Pending further information
23	Tenofovir alafenamide	Vemlidy	Infections	Rejected	Alternative(s) available in HADF with comparable benefits

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.